Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
17018895
DOI
10.1385/mo:23:3:377
PII: MO:23:3:377
Knihovny.cz E-zdroje
- MeSH
- buněčné kultury metody MeSH
- časové faktory MeSH
- CD4-pozitivní T-lymfocyty cytologie MeSH
- CD8-pozitivní T-lymfocyty cytologie MeSH
- fluoresceiny chemie MeSH
- homologní transplantace MeSH
- imunoterapie adoptivní metody MeSH
- interferon gama metabolismus MeSH
- lékařská onkologie metody MeSH
- lidé MeSH
- magnetismus MeSH
- mnohočetný myelom imunologie MeSH
- separace buněk MeSH
- sukcinimidy chemie MeSH
- T-lymfocyty imunologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- 5-(6)-carboxyfluorescein diacetate succinimidyl ester MeSH Prohlížeč
- fluoresceiny MeSH
- interferon gama MeSH
- sukcinimidy MeSH
Adoptive immunotherapy is a promising approach in the treatment of multiple myeloma. We have tested the identification, separation, and expansion of allogeneic myeloma-specific T cells in vitro. Irradiated myeloma cell line ARH 77 has been used to stimulate allogeneic CD4(+) and CD8(+) T lymphocytes. Activated myeloma-specific T cells that produced interferon-gamma were isolated using immunomagnetic beads and further expanded in vitro to numbers of up to 400 x 106 T cells. Specificity of the T lymphocytes was tested using a 5-(6-)carboxyfluoresceine diacetate succinimidyl ester (CFSE)-based cytotoxicity test. This study demonstrates the feasibility of identification and isolation of tumor-specific T cells from allogeneic donors that can be expanded in vitro to numbers useful for clinical applications.
Zobrazit více v PubMed
N Engl J Med. 1996 Jul 11;335(2):91-7 PubMed
Blood. 2003 Aug 15;102(4):1435-42 PubMed
J Immunol Methods. 2000 Sep 21;243(1-2):147-54 PubMed
Blood. 2002 Dec 1;100(12):3919-24 PubMed
Neoplasma. 2003;50(4):296-9 PubMed
Exp Hematol. 2003 Jan;31(1):73-80 PubMed
Blood. 2005 Aug 1;106(3):1123-9 PubMed
Blood. 2001 Nov 15;98(10):2992-8 PubMed
Blood. 2004 Jan 1;103(1):20-32 PubMed
Med Oncol. 2002;19(4):213-8 PubMed
Blood. 1999 Jul 15;94(2):673-83 PubMed
Nat Med. 2001 Oct;7(10):1159-62 PubMed
Eur J Immunol. 1999 Dec;29(12):4053-9 PubMed
Med Oncol. 2000 Feb;17(1):2-15 PubMed
Blood. 2001 Mar 15;97(6):1750-5 PubMed
Blood. 2004 Apr 1;103(7):2677-82 PubMed
Blood Rev. 1999 Sep;13(3):151-62 PubMed
J Immunol Methods. 2001 Mar 1;249(1-2):99-110 PubMed
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1180-4 PubMed
Cytometry A. 2003 Feb;51(2):107-18 PubMed
Br J Haematol. 2004 Sep;126(5):665-74 PubMed
Blood. 1998 Apr 1;91(7):2459-66 PubMed
